v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Revenue $ 58,351
Cost of goods sold 1,183,207
Gross loss (1,124,856)
Operating expenses:    
Research and development 307,730 760,417
Sales and marketing 268,355
General and administrative 1,665,822 3,062,326
Total operating expenses 1,973,552 4,091,098
Loss from operations (1,973,552) (5,215,954)
Other income (expense):    
Interest income 26,240 153,298
Change in fair value - warrant liability 1,080,600 1,072,800
Change in fair value - derivative liability 1,531,000 9,000
Unrealized loss on marketable securities (71,707) (35,019)
Realized gain on marketable securities 211,062 377,123
Other income, net 41,368
Total other income, net 2,818,563 1,577,202
Net income (loss) prior to provision for income taxes 845,011 (3,638,752)
Provision for income taxes
Net income (loss) 845,011 (3,638,752)
Dividends earned on Series H-7 convertible preferred stock (833,733) (452,086)
Accretion of discounts to redemption value of Series H-7 convertible preferred stock (1,686,854) (3,095,473)
Net loss attributable to common stockholders $ (1,675,576) $ (7,186,311)
Net loss per share basic $ (0.20) $ (1.46)
Net loss per share diluted $ (0.20) $ (1.46)
Basic weighted average Common Stock outstanding 8,541,466 4,929,490
Diluted weighted average Common Stock outstanding 8,541,466 4,929,490

Source